Ed Ponsi is an Educator and Author at FXStreet and TheStreet. With a background in finance and trading, he specializes in areas such as corporate finance, energy policy, and psychedelic research, making complex topics accessible to a wide audience. Ed has been featured in FXStreet and TheStreet, showcasing his expertise in finance, trading, and business economics.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Ed Ponsi's articles predominantly focus on investment analysis and data-driven insights. He frequently references data and charts to support his analyses. Therefore, he would likely be interested in pitches that offer unique data sets or innovative ways of visualizing financial information.
Given the nature of his coverage, Ed may be receptive to expert commentary from professionals with a strong background in finance, particularly those who can provide valuable insights backed by data analysis.
As there is no specific geographic focus mentioned for Ed's coverage, topics related to finance and investment analysis without regional constraints are likely to align well with his area of expertise.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Tesla and SpaceX share more than a CEO. Here’s what SpaceX’s lockup expiration could mean for Tesla stock.
It’s becoming commonplace for tech stocks to sell off after earnings beats.
Is outgoing Apple CEO Tim Cook smoothing the path for his successor?
Software stocks like Palantir and CrowdStrike are heating up as the sector regains favor with investors.
Single stock futures could change the way traders view individual stocks.
By: Ed Ponsi
With AI hedge fund Situational Awareness at the forefront, margin debt is rapidly accumulating.
With retail stocks slipping as earnings approach, we’re reducing our position.
By: Ed Ponsi
Is pharma heating up? Let’s chart four sector names and… Costco?
Tempus AI and Merck are key contributors to Moderna’s success.
A scheduled decline in prescription drug prices gives Target a sustainable edge over Walmart.
